Brian Wigdahl, Ph.D., is professor and chair of Microbiology and Immunology, director of the Institute for Molecular Medicine and Infectious Disease, and director of the institutes Center for Molecular Virology and Translational Neuroscience at the Drexel University College of Medicine. An internationally recognized molecular virologist, Dr. Wigdahl focuses his immediate research on the molecular mechanisms, treatment, and prevention of immunologic abnormalities, cancer, and progressive neurologic disorders caused by members of the retrovirus and herpesvirus families. He has a total of more than 180 published or in press peer-reviewed publications. Dr. Wigdahl has been funded by the National Institutes of
Brian Wigdahl, Ph.D., is professor and chair of Microbiology and Immunology, director of the Institute for Molecular Medicine and Infectious Disease, and director of the institutes Center for Molecular Virology and Translational Neuroscience at the Drexel University College of Medicine. An internationally recognized molecular virologist, Dr. Wigdahl focuses his immediate research on the molecular mechanisms, treatment, and prevention of immunologic abnormalities, cancer, and progressive neurologic disorders caused by members of the retrovirus and herpesvirus families. He has a total of more than 180 published or in press peer-reviewed publications. Dr. Wigdahl has been funded by the National Institutes of Health and other agencies, foundations, commercial sources for over 35 years, with awards totaling more than $40 million. A senior associate editor of the Journal of NeuroVirology, Dr. Wigdahl also served for six years as president of the International Society for NeuroVirology, and currently serves as treasurer of the Society. During his time at Penn State, Dr. Wigdahl was awarded the Samuel Hinkle Society Outstanding Young Investigator award and more recently at Drexel University College of Medicine, the Julian Marsh, MD, Faculty Scholar Award for excellence in scientific research, outstanding teaching skills, and consistent high quality leadership. Dr. Wigdahl is the 2013 recipient of the International Society for NeuroVirology Pioneer in Neurovirology Award presented in recognition of outstanding individual achievement in the field of neurovirology.
Han-Mou Tsai, M.D., formerly Professor of Medicine and Associated Head of the Unified Division of Hematology at Montefiore Medical Center and Albert Einstein College of Medicine and Professor of Medicine and Pathology and M. Elaine Eyster M.D. Professor of Hematology at Pennsylvania State University College of Medicine, is presently a consultant in Hematology. His research interests focus on the homeostasis of von Willebrand factor, ADAMTS13, platelet thrombosis, thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.
Han-Mou Tsai, M.D., formerly Professor of Medicine and Associated Head of the Unified Division of Hematology at Montefiore Medical Center and Albert Einstein College of Medicine and Professor of Medicine and Pathology and M. Elaine Eyster M.D. Professor of Hematology at Pennsylvania State University College of Medicine, is presently a consultant in Hematology. His research interests focus on the homeostasis of von Willebrand factor, ADAMTS13, platelet thrombosis, thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.
He obtained his medical degree and doctorate diploma from Aristotelian University, School of Medicine, Thessaloniki, Greece. Dr. Boudoulas had his training in Internal Medicine and Cardiology at The Aristotelian University and at The Ohio State University, Columbus, Ohio, USA. He was a Professor of Internal Medicine/Cardiology from 1980 till 2002 and Professor of Pharmacy from 1984 till 2002 at The Ohio State University.
He obtained his medical degree and doctorate diploma from Aristotelian University, School of Medicine, Thessaloniki, Greece. Dr. Boudoulas had his training in Internal Medicine and Cardiology at The Aristotelian University and at The Ohio State University, Columbus, Ohio, USA. He was a Professor of Internal Medicine/Cardiology from 1980 till 2002 and Professor of Pharmacy from 1984 till 2002 at The Ohio State University.
Kevin Knopf MD, MPH is a Health Economist and Health Services researcher as well as a practicing oncologist and site lead for oncology for Sutter Health in San Francisco. His research focuses on large scale data analytics, patterns and quality of care in oncology, health disparities in cancer screening, diagnosis, and treatment, and cost-effectiveness in cancer care. He started his research career in the Health Economics and Outcomes Research Branch at the NCI involved with the patterns of care studies, SEER-Medicare database, and the Prostate Cancer Outcomes Study. He is an editor at Value Based Cancer Care and the Journal
Kevin Knopf MD, MPH is a Health Economist and Health Services researcher as well as a practicing oncologist and site lead for oncology for Sutter Health in San Francisco. His research focuses on large scale data analytics, patterns and quality of care in oncology, health disparities in cancer screening, diagnosis, and treatment, and cost-effectiveness in cancer care. He started his research career in the Health Economics and Outcomes Research Branch at the NCI involved with the patterns of care studies, SEER-Medicare database, and the Prostate Cancer Outcomes Study. He is an editor at Value Based Cancer Care and the Journal of Community Oncology. He is also Vice President of the nonprofit Rooms that Rock 4 Chemo. He has clinical faculty positions at Dartmouth Medical School and the University of California, San Francisco School of Medicine; and was formerly adjunct faculty at the Johns Hopkins Oncology Center. He has been a co-investigator on numerous clinical trials and is former director of clinical research at the Annapolis Oncology Center. Dr. Knopf received an undergraduate degree in mechanical engineering from the Massachusetts Institute of Technology and his medical degree from the University of California, San Francisco School of Medicine. He completed his clinical training at Northwestern Medical School, the Memorial Sloan Kettering Cancer Center, and the National Cancer Institute. He obtained a MPH in Epidemiology and Statistics at the Johns Hopkins School of Public Health.
Assistant Professor, Department of Neurology, University of South Carolina, Charleston, SC 29425, USA (1998-2004). Associate Professor, Department of Neurosciences (Division of Neurology), University of South Carolina, Charleston, SC 29209, USA (2004-2007). Professor, Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC 29209, USA (2008-present). I have expertise in biochemistry, molecular biology, neuro-oncology, and neuroscience. Currently, my most important areas of investigation include neuro-oncology and neurological diseases. I have been conducting research for more than 20 years in different malignant diseases of blood, breast, brain, and adrenal gland. I also conduct molecular studies in neurodegenerative
Assistant Professor, Department of Neurology, University of South Carolina, Charleston, SC 29425, USA (1998-2004). Associate Professor, Department of Neurosciences (Division of Neurology), University of South Carolina, Charleston, SC 29209, USA (2004-2007). Professor, Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC 29209, USA (2008-present). I have expertise in biochemistry, molecular biology, neuro-oncology, and neuroscience. Currently, my most important areas of investigation include neuro-oncology and neurological diseases. I have been conducting research for more than 20 years in different malignant diseases of blood, breast, brain, and adrenal gland. I also conduct molecular studies in neurodegenerative disorders.
Wenlong Bai, Ph.D., Professor, Department of Pathology and Cell Biology Morsani College of Medicine received his graduate training and Ph.D. degree in Biochemistry and Molecular Biology from UT-GSBS at Houston and M. D. Anderson Cancer Center and postdoctoral training in Molecular Endocrinology from Baylor College of Medicine. In 1997, he joined USF as an assistant professor and become a full professor in 2007. He is a member of the graduate school of biomedical sciences at College of Medicine, a member of the Ph.D. program in Cancer Biology at Moffitt Cancer Center and a joint member of Cancer Biology and Evolution
Wenlong Bai, Ph.D., Professor, Department of Pathology and Cell Biology Morsani College of Medicine received his graduate training and Ph.D. degree in Biochemistry and Molecular Biology from UT-GSBS at Houston and M. D. Anderson Cancer Center and postdoctoral training in Molecular Endocrinology from Baylor College of Medicine. In 1997, he joined USF as an assistant professor and become a full professor in 2007. He is a member of the graduate school of biomedical sciences at College of Medicine, a member of the Ph.D. program in Cancer Biology at Moffitt Cancer Center and a joint member of Cancer Biology and Evolution research program at Moffitt. He is also a Visiting Professor in the Second Clinical Medical College & Second Hospital at Lanzhou University of P. R. China. Research in his laboratory focuses on the role of steroid hormone and vitamin D receptors in the development and treatment of human cancers.
Professor of Radiology and Director of Image-Guided Bio-Molecular Interventions Research, Attending Physician of Interventional Radiology, Department of Radiology at University of Washington School of Medicine. Senior Lecturer of Radiology at Kuopio University in Finland and an Attending Physician of Radiology qualified in European Community Countries. Research Interests are Interventional Radiology, Molecular Imaging, MRI of stem cell and gene therapies.
Professor of Radiology and Director of Image-Guided Bio-Molecular Interventions Research, Attending Physician of Interventional Radiology, Department of Radiology at University of Washington School of Medicine. Senior Lecturer of Radiology at Kuopio University in Finland and an Attending Physician of Radiology qualified in European Community Countries. Research Interests are Interventional Radiology, Molecular Imaging, MRI of stem cell and gene therapies.
Dr. Sugawara is Professor of Department of Advanced Biological Sciences for Regeneration Tohoku University, Graduate School of Medicine, Sendai, Japan. He graduated from Tohoku University School of Medicine in 1987 MD and PhD degree from Tohoku University, Graduate School of Medicine in 1991. He studied in Professor William Chins Lab Division of Genetics, Department of Medicine/Howard Hughes Medical Institute in Harvard Medical School until 1994. Thereafter, he came back to Tohoku University as Assistant Professor in Division of Nephrology Endocrinology and Vascular Medicine, Department of Medicine. His main research focus is to elucidate the role of nuclear hormone
Dr. Sugawara is Professor of Department of Advanced Biological Sciences for Regeneration Tohoku University, Graduate School of Medicine, Sendai, Japan. He graduated from Tohoku University School of Medicine in 1987 MD and PhD degree from Tohoku University, Graduate School of Medicine in 1991. He studied in Professor William Chins Lab Division of Genetics, Department of Medicine/Howard Hughes Medical Institute in Harvard Medical School until 1994. Thereafter, he came back to Tohoku University as Assistant Professor in Division of Nephrology Endocrinology and Vascular Medicine, Department of Medicine. His main research focus is to elucidate the role of nuclear hormone receptors especially retinoic acid receptor and peroxisome proliferator activated receptor gamma in the pathogenesis and treatment of hypertension atherosclerosis and kidney diseases. He is also doing many clinical works in Tohoku University Hospital, especially seeing patients related to endocrinology diabetes and hypertension Additionally. He is doing many teaching works in both School of Medicine and Graduate School of Medicine. Research interests are Molecular Biology of Nuclear Hormone Receptors, Etiology of High Blood Pressure, Pathophysiology of Diabetic Nephropathy, Gene Regulation of Aldosterone Synthesis, Epigenetics of Hypertension and Diabetes Mellitus.
Prof. Alberto Verrotti was born in Pescara on june 13,1959. After the high school diploma he graduated in Medicine at University of Chieti, Italy and he postgraduated in Paediatrics and Neurology at University of Chieti. He obtained PhD in Pediatrics at University of Rome, Italy. In 1983 was Visiting Doctor, University of Stockohlm, Sweden. From 1983 to 1986, he was Junior Research Fellow at University of Chieti, Italy. From 1991 to 1999 he was Research Fellow at University of Chieti, Italy. From 1999 to 2013 he was Associate Professor of Paediatrics at University of Chieti, Italy. From August 2013
Prof. Alberto Verrotti was born in Pescara on june 13,1959. After the high school diploma he graduated in Medicine at University of Chieti, Italy and he postgraduated in Paediatrics and Neurology at University of Chieti. He obtained PhD in Pediatrics at University of Rome, Italy. In 1983 was Visiting Doctor, University of Stockohlm, Sweden. From 1983 to 1986, he was Junior Research Fellow at University of Chieti, Italy. From 1991 to 1999 he was Research Fellow at University of Chieti, Italy. From 1999 to 2013 he was Associate Professor of Paediatrics at University of Chieti, Italy. From August 2013 to present is Associate Professor of Pediatrics and Director of Department of Pediatrics, University of Perugia, Italy.
Kumiko Saeki, MD, PhD was graduated from the Faculty of Medicine, Tokyo University (1988). After a two-year residency at Tokyo University Hospital, she started researches on hematology at the Institute of Medical Science, the University of Tokyo. She received Degree of Doctor from the Graduate School of Tokyo University (1995). From 1995-1999, she worked as a postdoctoral fellow at the Research Institute, International Medical Center of Japan (IMCJ). In 1999, she became the Division Chief of the Department of Hematology at Research Institute, IMCJ and started researches on regenerative medicine using primate embryonic stem (ES) cells. Subsequently, she started researches
Kumiko Saeki, MD, PhD was graduated from the Faculty of Medicine, Tokyo University (1988). After a two-year residency at Tokyo University Hospital, she started researches on hematology at the Institute of Medical Science, the University of Tokyo. She received Degree of Doctor from the Graduate School of Tokyo University (1995). From 1995-1999, she worked as a postdoctoral fellow at the Research Institute, International Medical Center of Japan (IMCJ). In 1999, she became the Division Chief of the Department of Hematology at Research Institute, IMCJ and started researches on regenerative medicine using primate embryonic stem (ES) cells. Subsequently, she started researches on human ES cells and iPS cells. She has established methods for directed differentiation of human ES/iPS cells into hematopoietic progenitor cells, vascular endothelial cells, hepatocytes and classical brown adipocytes. Since 2010, she has been the Director of the Division of Stem Cell Therapy, Department of Disease Control, Research Institute, National Center for Global Health and Medicine (NCGM). Her current research themes are therapeutics development for the treatments of glucose metabolism disorders by using human ES/iPS-derived brown adipocytes and ischemic diseases by using human ES/iPS-derived vascular endothelial cells.
Dr. Maoquan Chu received his Ph.D. degree from East China University of Science and Technology in 2001. He then did his postdoctoral work in school of life science and technology in Shanghai Jiaotong University, where he developed into nano-biomedicine. In 2004, he joined the school of life science and technology in Tongji University. He was granted the title of professor in 2008 at Tongji University. Now he is also a joint professor at Research Center for Translational Medicine at Shanghai East Hospital in China. His research interfaces with biology, medicine, pharmacy and materials science. His research focuses on cancer imaging
Dr. Maoquan Chu received his Ph.D. degree from East China University of Science and Technology in 2001. He then did his postdoctoral work in school of life science and technology in Shanghai Jiaotong University, where he developed into nano-biomedicine. In 2004, he joined the school of life science and technology in Tongji University. He was granted the title of professor in 2008 at Tongji University. Now he is also a joint professor at Research Center for Translational Medicine at Shanghai East Hospital in China. His research interfaces with biology, medicine, pharmacy and materials science. His research focuses on cancer imaging and therapy using nanotechnology.
Slobodan Vukicevic, is a full professor and head of Laboratory of Mineralized Tissues and Proteomic Center at the Center for Translational and Clinical Research, Medical School University of Zagreb. Scientific interests comprise bone and cartilage morphogenetic proteins and development of drugs for regeneration of bone, kidney, pancreas and heart muscle. Invited speaker at numerous international conferences and universities. Received several international awards for achievements in science. Author of more than 170 manuscripts cited 5700 times, inventor on 24 patents and editor of 4 books on BMPs. Founder and CEO of Genera Research, innovation-based biotechnology company developing a novel regenerative device
Slobodan Vukicevic, is a full professor and head of Laboratory of Mineralized Tissues and Proteomic Center at the Center for Translational and Clinical Research, Medical School University of Zagreb. Scientific interests comprise bone and cartilage morphogenetic proteins and development of drugs for regeneration of bone, kidney, pancreas and heart muscle. Invited speaker at numerous international conferences and universities. Received several international awards for achievements in science. Author of more than 170 manuscripts cited 5700 times, inventor on 24 patents and editor of 4 books on BMPs. Founder and CEO of Genera Research, innovation-based biotechnology company developing a novel regenerative device for treating long bone fractures and non-unions via coordinating the collaborative FP7 project OSTEOGROW. Research interests are Molecular mechanisms of bone healing, bone and cartilage morphogenetic proteins, signal transduction mechanisms in osteoblasts, and development of drugs for regeneration of bone, kidney, liver, pancreas and heart muscle. In addition, clinical trials are currently conducted for a novel osteoinductive drug for local administration to fractures of the appendicular skeleton with particular reference to long bones and periodontal tissue. In parallel, novel antifibrotic drugs are in preclinical development for preventing fibrosis and stimulating regeneration of chronic kidney disease, liver cirrhosis and acute myocardial infarction.
Prof. Weizhi Ji was the director of Kunming Institute of Zoology, Chinese Academy of Science in 1996-2005. He is currently the Professor and Chair of Yunnan Key Laboratory of Primate Biomedical Research. In 1985-1987, Prof. Ji worked as a scientist in Oregon National Primate Research Center and Smithsonian Institution in US. In 1995-1997, he held visiting professor position in University of Wisconsin. In 1996, Prof. Ji was the director of China-US Joint primate biology laboratory, which was set up by Kunming Institute of Zoology and Wisconsin Primate Research Center. Prof. Ji has been engaged in primate reproductive biology research for
Prof. Weizhi Ji was the director of Kunming Institute of Zoology, Chinese Academy of Science in 1996-2005. He is currently the Professor and Chair of Yunnan Key Laboratory of Primate Biomedical Research. In 1985-1987, Prof. Ji worked as a scientist in Oregon National Primate Research Center and Smithsonian Institution in US. In 1995-1997, he held visiting professor position in University of Wisconsin. In 1996, Prof. Ji was the director of China-US Joint primate biology laboratory, which was set up by Kunming Institute of Zoology and Wisconsin Primate Research Center. Prof. Ji has been engaged in primate reproductive biology research for several years and takes the lead in primate stem cell research in China. His lab reported the first gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting. His lab has established human, monkey, rabbit and mouse embryonic stem cell lines and adult stem cell lines. His study found the mechanism of embryonic stem cells differentiate into neural stem cells in vivo and the integration mechanisms in vitro. Now his research focuses on generation of transgenic monkeys, stem cell self-renewal mechanisms and stem cell replacement therapy research, where he has published a lot in high level magazines of this area, such as "Cell", "Cell Stem Cells", "PNAS", "Biology of Reproduction", "Human Reproduction" and other magazines.
Prof. Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 110 publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar's research has generated several patents/PCTs with more than five licensed patents
Prof. Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 110 publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar's research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1alpha and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. His research combines Immunology with state of the art and cutting edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualization to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar's main research objective is to understand and target the mechanisms involved at the molecular and sub cellular level which gives us an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focus on locked nucleic acid (LNA) LNA-modified aptamers conjugated 'double targeted nano-bullet nanocapsules' with natural anti-tumour proteins which specifically target cancer cells.
Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 200 peer-reviewed papers covering cancer biomarkers, proteomics, microRNAs, Chinese
Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr Cho has published over 200 peer-reviewed papers covering cancer biomarkers, proteomics, microRNAs, Chinese medicine and plenty of books including "MicroRNAs in cancer translational research", "An omics perspective on cancer research", "Supportive cancer care with Chinese medicine", etc. He serves as the editor-in-chief, editor and associate editor of a number of international medical journals. Dr Cho is also an international renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK). I have broad research interests, including cancer biomarkers discovery, lung cancer, nasopharyngeal carcinoma, microRNAs, proteomics, diabetes mellitus, Chinese medicine, integrative medicine.
Dr. Zhong Chao Han is a professor of Chinese Academy of Medical Sciences & Peking Union Medical College, Director of National Engineering Research Center of Stem Cells, academician of French National Academy of Technologies, and corresponding member of French National Academy of Medicine. Dr. Han works on hematology and stem cell biology, specially in the field of perinatal stem cells and their industrial and clinical application. To date, Dr. Han has published five books and more than 430 scientific articles in peer-review journals, of all published papers 230 are published in international journals. As the principal inventor, Dr. Han has
Dr. Zhong Chao Han is a professor of Chinese Academy of Medical Sciences & Peking Union Medical College, Director of National Engineering Research Center of Stem Cells, academician of French National Academy of Technologies, and corresponding member of French National Academy of Medicine. Dr. Han works on hematology and stem cell biology, specially in the field of perinatal stem cells and their industrial and clinical application. To date, Dr. Han has published five books and more than 430 scientific articles in peer-review journals, of all published papers 230 are published in international journals. As the principal inventor, Dr. Han has also obtained 26 scientific prizes and honors. His research interests are heart failure, clinical trials and race/ethnicity.
I am currently a Professor at Tongji University School of Medicine, Research Center for Translational Center, Shanghai East Hospital. After obtaining PhD degree in 2003 from Chinese Academy of Medical Sciences, I started my postdoctoral training at University of Pennsylvania School of Medicine and Thomas Jefferson University Kimmel Cancer Center. In 2009 I was assigned a faculty position in the track of research assistant professor at Thomas Jefferson University. After joining Tongji University in Shanghai in 2011, I focus on non-coding RNA regulation of breast cancer stem cells and drug-resistant breast cancer cells with a goal to find key molecules
I am currently a Professor at Tongji University School of Medicine, Research Center for Translational Center, Shanghai East Hospital. After obtaining PhD degree in 2003 from Chinese Academy of Medical Sciences, I started my postdoctoral training at University of Pennsylvania School of Medicine and Thomas Jefferson University Kimmel Cancer Center. In 2009 I was assigned a faculty position in the track of research assistant professor at Thomas Jefferson University. After joining Tongji University in Shanghai in 2011, I focus on non-coding RNA regulation of breast cancer stem cells and drug-resistant breast cancer cells with a goal to find key molecules inhibiting breast cancer relapse and metastasis.
Dr. Hu obtained his Ph.D degree from Shanghai Institute of Biochemistry and Cell Biology in 2000. He was first a postdoctoral scholar then a Senior Research Fellow in California Institute of Technology, where he discovered redox- and gas-sensing functions of the ubiquitin-proteasome pathways (Hu et al 2005 Nature; Hu et al 2008 PNAS). From late 2009 to the present, his lab has mainly focused on "Ub signaling and autophagy". Recent work by his team has led to the discovery of how Ub signaling might regulate autophagy and tumor suppression through controlling the formation of autophagy receptor complex (Liu et al
Dr. Hu obtained his Ph.D degree from Shanghai Institute of Biochemistry and Cell Biology in 2000. He was first a postdoctoral scholar then a Senior Research Fellow in California Institute of Technology, where he discovered redox- and gas-sensing functions of the ubiquitin-proteasome pathways (Hu et al 2005 Nature; Hu et al 2008 PNAS). From late 2009 to the present, his lab has mainly focused on "Ub signaling and autophagy". Recent work by his team has led to the discovery of how Ub signaling might regulate autophagy and tumor suppression through controlling the formation of autophagy receptor complex (Liu et al 2014 Cancer Cell), how direct regulation of p53 signaling by iron metabolism might contribute to tumorigenesis and tumor responses to iron-deprivation-based chemotherapy (Shen et al 2014 Cell Reports), and development of a systems biology tool to quantitatively profile protein degradation at proteome level (Yu et al 2014 Cell Research).
Dr. Barr is an Assistant Professor in the WVU School of Nursing and Emergency Medicine. She serves as the Associate Director of Clinical Translational Research in the WVU Stroke Center. Her training has spanned from basic preclinical models of neurological disease mechanism, to qualitative research methods to understand the human response to disease and the application of genetics and genomics for personalized medicine. Her program of research is centered on the use of genomic methodologies to identify biomarkers of neurological disease, understand their relationship with post-stroke inflammation and immunity, and define the contributing environmental factors related to health disparity in
Dr. Barr is an Assistant Professor in the WVU School of Nursing and Emergency Medicine. She serves as the Associate Director of Clinical Translational Research in the WVU Stroke Center. Her training has spanned from basic preclinical models of neurological disease mechanism, to qualitative research methods to understand the human response to disease and the application of genetics and genomics for personalized medicine. Her program of research is centered on the use of genomic methodologies to identify biomarkers of neurological disease, understand their relationship with post-stroke inflammation and immunity, and define the contributing environmental factors related to health disparity in underserved populations. My Research interests are: Stroke/Brain injury; immune system and recovery; translational approaches to science and medicine.
Thein H Oo received his medical degree from the Institute of Medicine II, Rangoon. He completed internal medicine training at the UK hospitals and at Albany Medical College, New York. He underwent Clinical Oncology training at Christie Hospital, UK, and Hematology-Oncology Clinical and Research Fellowship at St Elizabeths Medical Center, Boston, USA. After fellowship training, he joined the faculty of Tufts University School of Medicine, Boston. He has published over eighty manuscripts, book chapters and abstracts. He served on the Test Material Development Committee and Committee on Practice, both of American Society of Hematology. He currently serves on the
Thein H Oo received his medical degree from the Institute of Medicine II, Rangoon. He completed internal medicine training at the UK hospitals and at Albany Medical College, New York. He underwent Clinical Oncology training at Christie Hospital, UK, and Hematology-Oncology Clinical and Research Fellowship at St Elizabeths Medical Center, Boston, USA. After fellowship training, he joined the faculty of Tufts University School of Medicine, Boston. He has published over eighty manuscripts, book chapters and abstracts. He served on the Test Material Development Committee and Committee on Practice, both of American Society of Hematology. He currently serves on the Membership and Communications Committee of the International Society on Thrombosis and Haemostasis and on the editorial review board of four journals. He is currently an Associate Professor of Medicine at the University of Texas M.D. Anderson Cancer Center, Houston. His interests include hemostasis and thrombosis, consultative hematology and graduate medical education.
Vitaly Margulis, M.D., believes in working smarter, not harder, and he applies that philosophy to cancer care. An Assistant Professor of Urology at UT Southwestern Medical Center. Dr. Margulis uses robotics, laparoscopy, focal therapy, and open surgical techniques to treat soft-tissue tumors and kidney, prostate, bladder, testicular, penile, and adrenal cancers. His primary interest, however, is kidney cancer, and he is studying the genetic changes of the disease, what causes it to spread, and how to stop it. Dr. Margulis considers himself a shepherd who merely guides and gives medical advice. Patients, he says, have the most important role on
Vitaly Margulis, M.D., believes in working smarter, not harder, and he applies that philosophy to cancer care. An Assistant Professor of Urology at UT Southwestern Medical Center. Dr. Margulis uses robotics, laparoscopy, focal therapy, and open surgical techniques to treat soft-tissue tumors and kidney, prostate, bladder, testicular, penile, and adrenal cancers. His primary interest, however, is kidney cancer, and he is studying the genetic changes of the disease, what causes it to spread, and how to stop it. Dr. Margulis considers himself a shepherd who merely guides and gives medical advice. Patients, he says, have the most important role on his team. He believes they respond better to treatment when they are part of the equation. He also treats each patient as an individual and views his or her cancer as a separate entity. My research focus, during the two years of dedicated basic science training, was on understanding the molecular biology of renal cell carcinogenesis and progression as a model for developing novel diagnostic and therapeutic strategies for this disease.
Dr. Robert Wolk is Associate Professor of Medicine at Mayo Clinic College of Medicine (Rochester, MN) and Senior Director at Pfizer Global Research and Development (Groton, CT). He obtained his M.D. degree from Medical University of Warsaw (Poland) summa cum laude, his Ph.D. degree from University of Strathclyde (United Kingdom), and his D.Sc. degree from Medical University of Silesia (Poland). Dr. Wolk is trained in internal medicine and cardiovascular diseases. He is a member of the American Heart Association and European Society of Cardiology. Dr. Wolk is an author of almost 100 original scientific articles, editorials and book chapters. His
Dr. Robert Wolk is Associate Professor of Medicine at Mayo Clinic College of Medicine (Rochester, MN) and Senior Director at Pfizer Global Research and Development (Groton, CT). He obtained his M.D. degree from Medical University of Warsaw (Poland) summa cum laude, his Ph.D. degree from University of Strathclyde (United Kingdom), and his D.Sc. degree from Medical University of Silesia (Poland). Dr. Wolk is trained in internal medicine and cardiovascular diseases. He is a member of the American Heart Association and European Society of Cardiology. Dr. Wolk is an author of almost 100 original scientific articles, editorials and book chapters. His interests focus on translational research of novel cardiovascular and metabolic biomarkers and their application to diagnosis, treatment and risk stratification. Dr. Wolk is a member of the Adipocyte Working Group for the global multicenter randomized clinical trial BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). His research interests are dyslipidemia, atherosclerosis, hypertension, heart failure, obesity, adipose tissue, adipokines (leptin, adiponectin), sleep apnea.
Dr. Chen is an Associate Research Scientist at the Internal Medicine, Department of Cardiology, Yale University. Dr. Chen received her BS in Medical Technology from the Kaohsiung Medical University, Taiwan, her MS in Medical Technology from the National Taiwan University, Taiwan, and her PhD in Molecular Biology from the University of Maine. Dr. Chen did her postdoctoral training at the Yale University. Dr. Chens research interests include growth factor signaling, vascular cell phenotype, vascular cell inflammation, and transplant arteriosclerosis.
Dr. Chen is an Associate Research Scientist at the Internal Medicine, Department of Cardiology, Yale University. Dr. Chen received her BS in Medical Technology from the Kaohsiung Medical University, Taiwan, her MS in Medical Technology from the National Taiwan University, Taiwan, and her PhD in Molecular Biology from the University of Maine. Dr. Chen did her postdoctoral training at the Yale University. Dr. Chens research interests include growth factor signaling, vascular cell phenotype, vascular cell inflammation, and transplant arteriosclerosis.
Dr. Weihua is an Associate professor for Department of Surgery. He had received his Doctorate from Zhejiang University in Hangzhou City, China. He is PhD mentor of Zhejiang University. His research interest include biomarkers for oncology and oncogenesis.
Dr. Abdullah Shafique Ahmad is an Assistant Professor of Department of Anesthesiology. He received Travel Award from University of Florida-McKnight Brain Institute at International Stroke Conference 2014.He received his doctorate from University of Florida. His research interests include Behavioral and molecular neuropharmacology; focused on the neuroinflammatory and neurodegenerative processes which is a common feature in many neuropsychiatric and neurological disorders.
Dr. Abdullah Shafique Ahmad is an Assistant Professor of Department of Anesthesiology. He received Travel Award from University of Florida-McKnight Brain Institute at International Stroke Conference 2014.He received his doctorate from University of Florida. His research interests include Behavioral and molecular neuropharmacology; focused on the neuroinflammatory and neurodegenerative processes which is a common feature in many neuropsychiatric and neurological disorders.
David Della-Morte has received his MD and PhD degrees from University of Naples Federico II, Italy. Since 2006, Prof. Della-Morte is working at the Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA. Currently, he is Assistant Professor of Neurology at the same Institution, and he is also serving as Assistant Professor of Internal Medicine at School of Medicine, University of Rome Tor Vergata. Prof. Della-Morte has several open collaborations with research centers such as IRCCS San Raffaele Pisana in Rome. He is involved in both basic and clinical science in the field of risk factors
David Della-Morte has received his MD and PhD degrees from University of Naples Federico II, Italy. Since 2006, Prof. Della-Morte is working at the Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA. Currently, he is Assistant Professor of Neurology at the same Institution, and he is also serving as Assistant Professor of Internal Medicine at School of Medicine, University of Rome Tor Vergata. Prof. Della-Morte has several open collaborations with research centers such as IRCCS San Raffaele Pisana in Rome. He is involved in both basic and clinical science in the field of risk factors for cardiovascular and cerebrovascular diseases, and genetics. He is recipient of grants from American Heart Association, and he is serving as ad hoc reviewer of several reputed journals. He has authored more than 100 research articles/books. He is a member of The American Association for the Advancement of Science. His Research intrests are Ischemic Preconditioning in experimental and human studies. Neuroprotective agents in animal models of cardiac and cerebral ischemia. Neuroprotective role of stem cells transplant in stroke. Risk factors such as diabetes for cardiovascular disease. Epidemiological studies in large cohort populations such as Northern Manhattan Study (NOMAS). Genetic, pharmacogenetic and pharmacogenomic studis.
Dr. Edwin Choy was raised in Los Angeles, CA and graduated from Yale College in 1993 with a B.S. in Molecular Biophysics and Biochemistry. He received his MD and PhD in 2000 from New York University School of Medicine and then completed residency training at Massachusetts General Hospital. This was followed by a fellowship in medical oncology at the Dana Farber Cancer Institute and Massachusetts General Hospital. He then completed a postdoctoral research fellowship at the Broad Institute of MIT and Harvard. Upon completion of his fellowship, Dr. Choy joined the faculty in the Division of Hematology Oncology at Massachusetts
Dr. Edwin Choy was raised in Los Angeles, CA and graduated from Yale College in 1993 with a B.S. in Molecular Biophysics and Biochemistry. He received his MD and PhD in 2000 from New York University School of Medicine and then completed residency training at Massachusetts General Hospital. This was followed by a fellowship in medical oncology at the Dana Farber Cancer Institute and Massachusetts General Hospital. He then completed a postdoctoral research fellowship at the Broad Institute of MIT and Harvard. Upon completion of his fellowship, Dr. Choy joined the faculty in the Division of Hematology Oncology at Massachusetts General Hospital. His clinical practice and research focuses exclusively in the medical management of patients with sarcomas, gastrointestinal stromal tumors, chordomas, giant cell tumors, and desmoid tumors. He works closely with a team of world class surgical, orthopedic, and radiation oncologists as well as connective tissue pathologists and radiologists to provide optimal care for his patients.
Guangyu Li, MD, PhD is Assistant Professor at East Tennessee State Universits Quillen College of Medicine in Johnson City. He completed postdoctoral fellowships in both pathology and infectious diseases at the University of Texas. Prior to joining the faculty in the Department of Internal Medicines Division of Infectious Diseases, Dr. Li was an instructor at the University of Texas Medical Branch in Galveston. Dr. Li moved to the U.S. from his native China after earning his M.D. in 1997 and his Ph.D. in Infectious Diseases in 2005. Since then he has mentored two medicine fellows, one Ph.D. candidate, and three
Guangyu Li, MD, PhD is Assistant Professor at East Tennessee State Universits Quillen College of Medicine in Johnson City. He completed postdoctoral fellowships in both pathology and infectious diseases at the University of Texas. Prior to joining the faculty in the Department of Internal Medicines Division of Infectious Diseases, Dr. Li was an instructor at the University of Texas Medical Branch in Galveston. Dr. Li moved to the U.S. from his native China after earning his M.D. in 1997 and his Ph.D. in Infectious Diseases in 2005. Since then he has mentored two medicine fellows, one Ph.D. candidate, and three medical school students. He is a member of the Scientific Society of Sigma Xi, the American Society for Virology, and the American Society of Microbiology. Dr. Lis research interests include the pathogenesis of viruses- particularly the human immunodeficiency virus (HIV) and those that cause hepatitis, encephalitis, and hemorrhagic fevers. A seasoned researcher, Dr. Lis current projects are designed to assess the role of an identified gene, CD63, to HIV-1 replication in primary human macrophages, and generating and identifying nuclease-resistant phosphorothioate thioaptamers against hepatitis C infection. Along with his colleague, Monique Ferguson, Dr. Li was awarded a non-provisional patent in 2010 for detection of hepatitis C virus RNA. Author of more than 100 peer-reviewed journal articles, Dr. Li sits on the editorial board of the publication, Journal of Bioterrorism and Biodefense, and he has served as a reviewer for several additional publications, including the Journal of Applied Microbiology and Hepatic Medicine: Evidence and Research.
Dr. Wei-Hsiung Yang, Ph.D., is Assistant Professor at the Department of Biomedical Sciences, Mercer University School of Medicine, Savannah campus, GA, USA. Dr. Yang received his BS in Biology from National Sun Yat-sen University in Taiwan and his Ph.D. in Endocrine and Reproductive Physiology from Colorado State University. Dr. Yang completed postdoctoral trainings at the University of Texas Southwestern Medical Center at Dallas and University of Michigan Medical School. Dr. Yang's current research interests include establishing the principle of tumor suppressors relay between FOX proteins and noncoding RNA; regulation and function of post-translational protein modifications; identifying the cancer-causing genes and
Dr. Wei-Hsiung Yang, Ph.D., is Assistant Professor at the Department of Biomedical Sciences, Mercer University School of Medicine, Savannah campus, GA, USA. Dr. Yang received his BS in Biology from National Sun Yat-sen University in Taiwan and his Ph.D. in Endocrine and Reproductive Physiology from Colorado State University. Dr. Yang completed postdoctoral trainings at the University of Texas Southwestern Medical Center at Dallas and University of Michigan Medical School. Dr. Yang's current research interests include establishing the principle of tumor suppressors relay between FOX proteins and noncoding RNA; regulation and function of post-translational protein modifications; identifying the cancer-causing genes and tumor-suppressive genes, targets, and pathways; identifying novel regulators of p53 tumor suppressor; cancer prevention through diet. Dr. Yang is a member of several professional societies including AAAS, AACR, the Endocrine Society, and SSR.
Dr. Yaniv is an assistant professor in Biomedical Engineering at the Technion-IIT, Israel. Dr. Yael Yaniv received her BSc in both Electrical and Mechanical Engineering (cum laude), her MSc in Electrical Engineering (summa cum laude), and her PhD in Biomedical Engineering all from the Technion-IIT, Israel. She was a postdoctoral fellow in cardiovascular science at the National Institute on Aging, National Institutes of Health, under Dr. Edward Lakatta. She has been honored by the International Society of Heart Research and the Gordon Conference (both Cardiac Arrhythmia Mechanisms and Cardiac Regulatory Mechanisms) poster awards. She is currently the PI of Laboratory
Dr. Yaniv is an assistant professor in Biomedical Engineering at the Technion-IIT, Israel. Dr. Yael Yaniv received her BSc in both Electrical and Mechanical Engineering (cum laude), her MSc in Electrical Engineering (summa cum laude), and her PhD in Biomedical Engineering all from the Technion-IIT, Israel. She was a postdoctoral fellow in cardiovascular science at the National Institute on Aging, National Institutes of Health, under Dr. Edward Lakatta. She has been honored by the International Society of Heart Research and the Gordon Conference (both Cardiac Arrhythmia Mechanisms and Cardiac Regulatory Mechanisms) poster awards. She is currently the PI of Laboratory of Bioenergetic and Bioelectric system. Research interests are Atrial fibrillation, Bioenergetics, Calcium signaling, Cardiac electrophysiology, Cell Biophysics, Heart rate variability analysis, Mathematical modeling of the biochemical and bioenergetics signaling in the heart, Mechanical interaction of the mitochondria and the cytoskeleton, Mobile health, Sinoatrial node cells activity.
Rivka R. Colen, MD, is an Assistant Professor (tenure-track) in the Section of Neuroradiology, Department of Diagnostic Radiology at the University of Texas MD Anderson Cancer Center (MDACC) and specializes in quantitative imaging analysis/biomarkers and clinical, translational and preclinical imaging genomics, radiomics, big data and image guided therapy in brain tumors. She has pioneered the field of imaging genomics in brain tumors and published the first paper on quantitative imaging genomics. She spearheads the Cancer Genomic Atlas (TCGA) Imaging- Genomic projects which discovers and correlated genes and microRNA in brain tumors with MR imaging (termed imaging genomics or radiogenomics). She
Rivka R. Colen, MD, is an Assistant Professor (tenure-track) in the Section of Neuroradiology, Department of Diagnostic Radiology at the University of Texas MD Anderson Cancer Center (MDACC) and specializes in quantitative imaging analysis/biomarkers and clinical, translational and preclinical imaging genomics, radiomics, big data and image guided therapy in brain tumors. She has pioneered the field of imaging genomics in brain tumors and published the first paper on quantitative imaging genomics. She spearheads the Cancer Genomic Atlas (TCGA) Imaging- Genomic projects which discovers and correlated genes and microRNA in brain tumors with MR imaging (termed imaging genomics or radiogenomics). She has received numerous funding and awards for her work in this field, including the Siemens Outstanding Research Award/Grant, ASNR research grant, and RSNA research fellow grant. Dr. Colen serves as the chair of the American Society of Neuroradiology Imaging Genomics Working Group, and is also the co-director of the Quantitative Imaging Analysis Core at MDACC as well as the lead principal investigator of the TCGA Glioma Research Phenotype Group at MDACC. Research interests are preclinical/translational and clinical research which capitalizes on imaging genomics and neurooncology, field of imaging genomic screening and imaging genomics in brain tumors and published the first paper on quantitative imaging genomics.
Interested in developing new treatment modalities for pediatric solid tumors and cancer in general. Interested in targeting critical points in cancer cells with sparing of normal cells based on better understanding of cancer biology, Stem cells from hematopoietic origin and cord blood, glycolysis inhibition in treatment of cancer and research related to cancer in pediatrics. Using new experimental treatments e.g. siRNA against target oncogene RNA in treatment of cancer, Publications in doctor degree are related to glycolysis inhibition as a treatment for pediatric cancer (for glioma and glioblastoma cells). His research interests are research in cancer treatment, nutritional therapy and
Interested in developing new treatment modalities for pediatric solid tumors and cancer in general. Interested in targeting critical points in cancer cells with sparing of normal cells based on better understanding of cancer biology, Stem cells from hematopoietic origin and cord blood, glycolysis inhibition in treatment of cancer and research related to cancer in pediatrics. Using new experimental treatments e.g. siRNA against target oncogene RNA in treatment of cancer, Publications in doctor degree are related to glycolysis inhibition as a treatment for pediatric cancer (for glioma and glioblastoma cells). His research interests are research in cancer treatment, nutritional therapy and prophetic medicine.
Sharath P. Sasi received his B. E. degree in Electronics and Instrumentation Engineering from Tamil Nadu College of Engineering, India. Subsequently he finished his graduate studies in Biomedical Engineering at Louisiana Tech University, where his research interests included in vivo bioengineering of implantable micro/nano-glucosensors. Following this, he joined the Childrens hospital of Philadelphia where he was the lead researcher in RNA probe design and in-situ hybridization on NCBI/NIH GENSAT project. Currently Sharath is Senior Research Associate at the Cardiovascular Research Center, GeneSys Research Institute, Boston. His current research focuses on long-term Cardiovascular degenerative risks associated with low dose ionizing radiation
Sharath P. Sasi received his B. E. degree in Electronics and Instrumentation Engineering from Tamil Nadu College of Engineering, India. Subsequently he finished his graduate studies in Biomedical Engineering at Louisiana Tech University, where his research interests included in vivo bioengineering of implantable micro/nano-glucosensors. Following this, he joined the Childrens hospital of Philadelphia where he was the lead researcher in RNA probe design and in-situ hybridization on NCBI/NIH GENSAT project. Currently Sharath is Senior Research Associate at the Cardiovascular Research Center, GeneSys Research Institute, Boston. His current research focuses on long-term Cardiovascular degenerative risks associated with low dose ionizing radiation and breast cancer radiotherapy regimen. He has numerous publications in peer reviewed scientific journals like Oncogene, FASEB, PLOS One and JBC to name a few. He has also presented his work at numerous national and international conferences.
Stefano Morara is a senior research scientist at the Neuroscience Institue of C.N.R. in Milano. Following his education at the University of Padova, where he obtained the degree in Biological Sciences by a thesis in biochemistry, he moved its scientific interest to the neuroscience field. Deriving from the initial analysis of neuropeptides involvement in cerebellar development, his present main scientific focus is the modulation of cellular mechanisms of neuroinflammation (in particular, mediated by glia cells) by means of neuropeptides, and the molecular mechanisms driving chronic microglia activation in human diseases with neuroinflammatory or neurotoxic/neurodegenerative basis. Another focus of its research
Stefano Morara is a senior research scientist at the Neuroscience Institue of C.N.R. in Milano. Following his education at the University of Padova, where he obtained the degree in Biological Sciences by a thesis in biochemistry, he moved its scientific interest to the neuroscience field. Deriving from the initial analysis of neuropeptides involvement in cerebellar development, his present main scientific focus is the modulation of cellular mechanisms of neuroinflammation (in particular, mediated by glia cells) by means of neuropeptides, and the molecular mechanisms driving chronic microglia activation in human diseases with neuroinflammatory or neurotoxic/neurodegenerative basis. Another focus of its research is the technical development in two areas, CNS drug delivery and quantitative image analysis. He also served as ad hoc for journals in the neuroscience field, such as Neuropeptides, Neuroscience and The Journal of Neurobiology. His research interests are Neuropeptides, neuropeptide receptors, neuroinflammation, microglia, multiple sclerosis, Parkinson’s disease, CNS homeostasis, glia, neuron-glia interaction, cerebellar development and plasticity.
Dr. Jianzhong Ma is statistician at the Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston. Dr. Ma has been focused on developing, implementing and applying novel statistical and computational methodologies for genetic and genomics data analysis. Dr. Mas research interests include segregation and linkage analysis using Bayesian Markov chain Monte Carlo approach, detecting and correcting population stratifications using principal components analysis, detecting and genotyping chromosomal inversions using SNP microarray data and sequence and approaches to conducting genome-wide association tests for inversions. He is also interested in developing novel approaches to detecting gene-gene
Dr. Jianzhong Ma is statistician at the Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston. Dr. Ma has been focused on developing, implementing and applying novel statistical and computational methodologies for genetic and genomics data analysis. Dr. Mas research interests include segregation and linkage analysis using Bayesian Markov chain Monte Carlo approach, detecting and correcting population stratifications using principal components analysis, detecting and genotyping chromosomal inversions using SNP microarray data and sequence and approaches to conducting genome-wide association tests for inversions. He is also interested in developing novel approaches to detecting gene-gene and gene-environment interactions. Dr. Mas collaborative research in applied genetic epidemiology has been focused on genetic and environmental factors, as well as their interplay, underlying various chronic diseases, such as lung cancer, melanoma, cardiovascular disease, psoriasis, and autism spectrum disorder.
Dr. Ghali is Professor of Medicine at Mercer University. He is the Associate Chair for Clinical Research and Chief of Cardiology. He received his MD degree from Damascus University in Syria. He is board certified in internal medicine and cardiovascular medicine. As principal investigator, Dr. Ghali has conducted over 200 clinical trials predominantly in heart failure and has contributed to the medical literature more than 200 publications, predominantly in the field of heart failure. He currently serves on the editorial board of the American Heart Journal, Journal of Cardiac Failure, European Journal of Heart Failure, JACC: Heart
Dr. Ghali is Professor of Medicine at Mercer University. He is the Associate Chair for Clinical Research and Chief of Cardiology. He received his MD degree from Damascus University in Syria. He is board certified in internal medicine and cardiovascular medicine. As principal investigator, Dr. Ghali has conducted over 200 clinical trials predominantly in heart failure and has contributed to the medical literature more than 200 publications, predominantly in the field of heart failure. He currently serves on the editorial board of the American Heart Journal, Journal of Cardiac Failure, European Journal of Heart Failure, JACC: Heart Failure, Current Cardiology Review, Open Heart Failure Journal, World Journal of Cardiology, American Journal of Cardiovascular Disease, World Journal of Cardiovascular Diseases, Journal of Cardiology and Vascular Medicine, Advances in Medicine, Scholarena Journal of Cardiology and Journal of Experimental Cardiology and Research. He currently serves as Senior Editor for Congestive Heart Failure and as Associate Editor for Aging Health. He has served as a member of several steering committees, adjudication committees and data and safety monitoring boards in various heart failure trials. He came to Mercer from Detroit where he held the positions of Director of Cardiovascular clinical trials and the heart failure program at the Cardiovascular Institute, Detroit Medical Center, Chief of Cardiology, Detroit Receiving Hospital and Associate Chair for Research at Wayne State University.
Dr. Patel received his doctorate in Pharmacy from the University of North Carolina Eshelman School of Pharmacy. Upon receiving his degree, Dr. Patel completed an oncology pharmacogenomics postdoctoral fellowship at the UNC Eshelman School of Pharmacy and the UNC Institute for Pharmacogenomics and Individualized Therapy. Dr. Patel is currently employed as Chief, Pharmacology Research, Phase I Trials at the Carolinas HealthCare Systems Levine Cancer Institute, and Adjunct Assistant Professor at the UNC Eshelman School of Pharmacy. His primary role and research interests include the discovery, translation and implementation of pharmacology-based approaches to personalize cancer therapy, including pharmacogenomics, pharmacokinetics and pharmacodynamics.
Dr. Patel received his doctorate in Pharmacy from the University of North Carolina Eshelman School of Pharmacy. Upon receiving his degree, Dr. Patel completed an oncology pharmacogenomics postdoctoral fellowship at the UNC Eshelman School of Pharmacy and the UNC Institute for Pharmacogenomics and Individualized Therapy. Dr. Patel is currently employed as Chief, Pharmacology Research, Phase I Trials at the Carolinas HealthCare Systems Levine Cancer Institute, and Adjunct Assistant Professor at the UNC Eshelman School of Pharmacy. His primary role and research interests include the discovery, translation and implementation of pharmacology-based approaches to personalize cancer therapy, including pharmacogenomics, pharmacokinetics and pharmacodynamics. In addition, Dr.Patel helps to lead the clinical pharmacology activities for early phase trials at the Levine Cancer Institute. Dr. Patel teaches various oncology and pharmacogenomic lectures at the UNC Eshelman School of Pharmacy and collaborates with the UNC Center for Pharmacogenomics and Individualized Therapy on similar research. Dr. Patel is Editorial Board Member for HemOnc Today, and Member of ASCO, AACR and HOPA.
Dr. Hitesh Soni has received his Ph.D. degree from Gujarat University, India. He served as Associate Research Scientist in Drug Discovery unit of "Zydus Cadila" for eight years. He worked on cardio-renal drug discovery targets and actively involved in screening of novel molecules using preclinical models of diseases. Since 2011, Dr. Soni is working as post-doctoral researcher at Department of Physiology, University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA in cardio-renal field using translational piglet model. He is recipient of "Leonard Share Young Investigator Award" in 2014 by UTHSC in recognition of outstanding basic research in the Cardiovascular-Renal
Dr. Hitesh Soni has received his Ph.D. degree from Gujarat University, India. He served as Associate Research Scientist in Drug Discovery unit of "Zydus Cadila" for eight years. He worked on cardio-renal drug discovery targets and actively involved in screening of novel molecules using preclinical models of diseases. Since 2011, Dr. Soni is working as post-doctoral researcher at Department of Physiology, University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA in cardio-renal field using translational piglet model. He is recipient of "Leonard Share Young Investigator Award" in 2014 by UTHSC in recognition of outstanding basic research in the Cardiovascular-Renal field. He has published 13 research articles and one patent. One of his research articles has been awarded for prestigious "Professor M. L. Khorana Memorial Prize". He is serving as Associate Editor, Medcrave Online Journal of Toxicology (MOJT) by MedCrave Publishing Group and ad hoc reviewer of several reputed journals.
Giuditta Mannelli, she is 30 is a Senior Resident in ENT and Head and Neck Surgery at the University of Florence. She has been abroad for clinical and surgical experiences, as vsiting resident at Center for Laryngeal Surgery and Voice Rehabilitation, directed by Dr S.M. Zeitels, at Massachussetts General Hospital in Boston, as clinical laryngological fellow at ENT Royal Hospital in London and she worked as clinical thyroid and head and neck senior fellow for four months at Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK. Her main clinical and surgical skills are laryngology and head and neck
Giuditta Mannelli, she is 30 is a Senior Resident in ENT and Head and Neck Surgery at the University of Florence. She has been abroad for clinical and surgical experiences, as vsiting resident at Center for Laryngeal Surgery and Voice Rehabilitation, directed by Dr S.M. Zeitels, at Massachussetts General Hospital in Boston, as clinical laryngological fellow at ENT Royal Hospital in London and she worked as clinical thyroid and head and neck senior fellow for four months at Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK. Her main clinical and surgical skills are laryngology and head and neck surgery; and her main research interestes are: cancer stem cells in head and neck cancers; the role of pharyngo-laryngeal reflux in cancerogenesis in laryngeal cancer patients; new surgical devices in head and neck surgery and new diagnostic techniques in laryngeal pathologies, mini-invasive and conservative head and neck surgery. She has published more than 20 papers in reputed journals and has been serving as an editorial board member of repute. She won several National research awards and she took part to many congresses and courses. She also spent three weeks in Uganda for a charity thyroid camp at St. Mary’s Hospital in Lacor. She a voluntary member of a National Association for home care of advanced stage cancer patients, A.T.T. (Associazione Tumori Toscana).
Dale Ding obtained his M.D. from Duke University and is currently a senior neurosurgery resident at the University of Virginia. He has published over 100 articles, primarily in the field of cerebrovascular disease and in top subspecialty journals, such as the Journal of Neurosurgery, Neurosurgery, American Journal of Neuroradiology, Cerebrovascular Diseases, and Journal of Cerebral Blood Flow and Metabolism, and has presented over 40 abstracts at national and regional meetings. He serves as the Associate Editor of Neuroimmunology and Neuroinflammation and presides on the editorial boards of JSciMed Neurosurgery and Spine, Journal of Cerebrovascular Disease, Austin Journal of Cerebrovascular Disease
Dale Ding obtained his M.D. from Duke University and is currently a senior neurosurgery resident at the University of Virginia. He has published over 100 articles, primarily in the field of cerebrovascular disease and in top subspecialty journals, such as the Journal of Neurosurgery, Neurosurgery, American Journal of Neuroradiology, Cerebrovascular Diseases, and Journal of Cerebral Blood Flow and Metabolism, and has presented over 40 abstracts at national and regional meetings. He serves as the Associate Editor of Neuroimmunology and Neuroinflammation and presides on the editorial boards of JSciMed Neurosurgery and Spine, Journal of Cerebrovascular Disease, Austin Journal of Cerebrovascular Disease & Stroke, and Austin Journal of Radiation Oncology & Cancer. Additionally, he serves as an ad hoc reviewer for over 20 journals, including Neurology, Experimental Biology and Medicine, and British Journal of Neurosurgery. His research interests areRadiosurgery outcomes for cerebral arteriovenous malformations and skull base meningiomas, pathogenesis of intracranial aneurysms, role of inflammation in cerebrovascular disease, endovascular treatment of intracranial aneurysms and vascular malformations, surgical treatment of intracranial aneurysms and vascular malformations.
Dr. Bin Yan is a Research Assistant Professor, LKS Faculty of Medicine and Department of Physiology, The University of Hong Kong. His research focuses on development and application of bioinformatics and systems biology approaches, including inference of multilevel gene regulatory networks, identification of biomarkers targeting stem cells, cancer and human diseases, and integrative analysis of next generation sequencing data.
Dr. Bin Yan is a Research Assistant Professor, LKS Faculty of Medicine and Department of Physiology, The University of Hong Kong. His research focuses on development and application of bioinformatics and systems biology approaches, including inference of multilevel gene regulatory networks, identification of biomarkers targeting stem cells, cancer and human diseases, and integrative analysis of next generation sequencing data.
Alberto Martinez-Castelao has been Assistant Prof. of Medicine at Barcelona University and Head of Dialysis Division, Nephrology department, at Bellvitges University Hospital, in Hospitalet, Barcelona, Spain. From 1st December 2013 is Emeritus consultant at the same hospital. He has co-authored 200 peer-review papers, (PubMed see: Castelao AM, 107; Martínez-Castelao A, 87), 72 book chapters, 350 national & 175 international communications. He has pronounced 140 invited conferences in Spain, Latin-America and other countries. Main areas of clinical investigation: Progression of Chronic kidney Disease, Vascular risk in CKD, Diabetes & kidney damage, Anemia, Nephrotoxicity, Bone & Mineral Disorders in CKD, Haemodialysis
Alberto Martinez-Castelao has been Assistant Prof. of Medicine at Barcelona University and Head of Dialysis Division, Nephrology department, at Bellvitges University Hospital, in Hospitalet, Barcelona, Spain. From 1st December 2013 is Emeritus consultant at the same hospital. He has co-authored 200 peer-review papers, (PubMed see: Castelao AM, 107; Martínez-Castelao A, 87), 72 book chapters, 350 national & 175 international communications. He has pronounced 140 invited conferences in Spain, Latin-America and other countries. Main areas of clinical investigation: Progression of Chronic kidney Disease, Vascular risk in CKD, Diabetes & kidney damage, Anemia, Nephrotoxicity, Bone & Mineral Disorders in CKD, Haemodialysis and Haemodiafiltration, Teaching & Medical education. He has participated in more than 60 trials in diabetes, anaemia, dialysis, progression of CKD, CKD and cardio-vascular risk as well as in renal transplantation. He has been the president of the Spanish Society of Nephrology, S.E.N., from October 2008 to October 2014.
All articles are fully peer reviewed, free to access and can be downloaded from our ClinMed archive.
Clinical Medical Image Library: 93.51
International Journal of Critical Care and Emergency Medicine: 92.83
International Journal of Sports and Exercise Medicine: 91.84
International Journal of Womens Health and Wellness: 91.79
Journal of Musculoskeletal Disorders and Treatment: 91.73
Journal of Geriatric Medicine and Gerontology: 91.55
Journal of Infectious Diseases and Epidemiology: 91.55
Clinical Medical Reviews and Case Reports: 91.40
International Archives of Nursing and Health Care: 90.87
International Journal of Ophthalmology and Clinical Research: 90.80
International Archives of Urology and Complications: 90.73
Journal of Clinical Nephrology and Renal Care: 90.33
Journal of Family Medicine and Disease Prevention: 89.99
Journal of Clinical Gastroenterology and Treatment: 89.54
Journal of Dermatology Research and Therapy: 89.34
International Journal of Clinical Cardiology: 89.24
International Journal of Radiology and Imaging Technology: 88.88
Obstetrics and Gynaecology Cases - Reviews: 88.42
International Journal of Blood Research and Disorders: 88.22
International Journal of Diabetes and Clinical Research: 87.97